CollPlant Biotechnologies CLGN
NASDAQ CLGN
$4.12 +0.09 (+2.23%)
At close: Nov 9, 2026 · 4:00 PM EST

CollPlant Biotechnologies (CLGN) Return on Sales [ROS] (2017 - 2026)

Updated

CollPlant Biotechnologies (CLGN) posted Return on Sales [ROS] of 8206.48% for the quarter ended Jun 30, 2026, up 6431.06 percentage points from 1775.42% a year earlier and up 12473.60 percentage points from the prior quarter.

Analysis

CollPlant Biotechnologies (CLGN) Return on Sales [ROS] (2017 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Return on Sales [ROS] at CollPlant Biotechnologies was -285.85%, up 4.99 percentage points year-over-year; for the year ended Dec 31, 2025, it was -484.31%, up 2865.40 percentage points from the prior year.

  • Annual Return on Sales [ROS] shows a five-year change of -393.08 percentage points (years ended Dec 2020 to Dec 2025).
  • In prior years, CollPlant Biotechnologies' Return on Sales [ROS] was -3349.71% in the year ended Dec 31, 2024 (-3281.16 pp), -68.55% in the year ended Dec 31, 2023 (+5649.51 pp), -5718.06% in the year ended Dec 31, 2022 (-5718.48 pp) and 0.42% in the year ended Dec 31, 2021 (+91.65 pp).
  • The figure for the quarter ended Jun 30, 2026 stands as the highest quarterly Return on Sales [ROS] in data going back to the quarter ended Dec 31, 2017.
  • On a year-over-year basis, Return on Sales [ROS] increased in three of the last eight quarters, with an average year-over-year change of +43.16 percentage points.
  • The strongest year-over-year quarter for Return on Sales [ROS] in the past five years was the quarter ended Sep 30, 2025, with a gain of 108995.45 percentage points; the weakest was the quarter ended Sep 30, 2024, with a drop of 102847.67 percentage points.
  • According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -4267.12% (quarter ended Mar 30, 2026), -5250.00% (quarter ended Dec 31, 2025) and -4554.55% (quarter ended Sep 30, 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn 52.42%
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn 24.35%
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn 36.01%
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn 30.89%
5 Novartis Ag 316.85 Bn 290.09 Bn - -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn 29.12%
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn 35.79%
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn 41.71%
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn 32.98%
10 CollPlant Biotechnologies 4.98 Mn -17.38 Mn -456,000.00 -2,437.96%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -2,437.96%
Dec 31, 2025 -5,250.00%
Sep 30, 2025 -4,554.55%
Jun 30, 2025 -1,775.42%
Mar 31, 2025 -80.19%
Dec 31, 2024 -2,423.17%
Sep 30, 2024 -113,550.00%
Jun 30, 2024 -1,769.48%
Mar 31, 2024 4,417.35%
Dec 31, 2023 -1,694.98%
Sep 30, 2023 -10,702.33%
Jun 30, 2023 55.74%
Mar 31, 2023 812.70%
Dec 31, 2022 -8,062.07%
Sep 30, 2022 -4,099.08%
Jun 30, 2022 -6,340.91%
Dec 31, 2021 -1,227.10%
Sep 30, 2021 -2,210.00%
Jun 30, 2021 -443.27%
Mar 31, 2021 69.14%
API Access

CollPlant Biotechnologies Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=CLGN&period=max&api_key=YOUR_API_KEY